抗体
选项
-
Rovelizumab (anti-CD11a&CD18)
- 简短描述: Purity≥95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG4
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 339086-79-2SMILES: [Rovelizumab] -
Galiximab (anti-CD80)关联靶标: CD80
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 357613-77-5 -
CD80 Armenian Hamster mAb关联靶标: CD80
- 简短描述: mAb (16-10A1); Armenian Hamster anti Mouse CD80 Antibody; Flow; Unconjugated
- 种属反应性: 小鼠(Mouse)
- 亚型: Armenian Hamster IgG
- 宿主种属: 亚美尼亚仓鼠(Armenian hamster)
- 克隆号: 16-10A1
- 偶联: Unconjugated
-
CD18 Mouse mAb关联靶标: ITGB2
- 简短描述: mAb (HI18a); Mouse anti Human CD18 Antibody; Flow; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Mouse IgG1
- 宿主种属: 小鼠(Mouse)
- 克隆号: HI18a
- 偶联: Unconjugated
-
Erlizumab (anti-CD18)关联靶标: ITGB2
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 211323-03-4 -
CD80 Mouse mAb关联靶标: CD80
- 简短描述: mAb (3H5); Mouse anti Rat CD80 Antibody; Flow, in vitro CD80 blockade; Unconjugated
- 种属反应性: 大鼠(Rat)
- 亚型: Mouse IgG1
- 宿主种属: 小鼠(Mouse)
- 克隆号: 3H5
- 偶联: Unconjugated
-
CD18 Rat mAb关联靶标: ITGB2
- 简短描述: mAb (M18/2); Rat anti Mouse CD18 Antibody; in vivo LFA-1 neutralization, Flow; Unconjugated
- 种属反应性: 小鼠(Mouse)
- 亚型: Rat IgG2a
- 宿主种属: 大鼠(Rat)
- 克隆号: M18/2
- 偶联: Unconjugated
-
Recombinant CD80 Antibody关联靶标: CD80
- 简短描述: Recombinant; Rabbit anti Human CD80 Antibody; WB; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Rabbit IgG
- 宿主种属: 兔(Rabbit)
- 偶联: Unconjugated
-
CD18 Rat mAb (Biotin)关联靶标: ITGB2
- 简短描述: mAb (M18/2); Rat anti Mouse CD18 Antibody (Biotin); Flow Cytometry
- 种属反应性: 小鼠(Mouse)
- 亚型: Rat IgG2a
- 宿主种属: 大鼠(Rat)
- 克隆号: M18/2
- 偶联: Biotin
首页
400-620-6333








